ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2014, Vol. 23 ›› Issue (1): 84-88.

• 论文 • 上一篇    下一篇

肾移植术后咪唑立宾的临床应用

  

  • 出版日期:2014-02-28 发布日期:2014-02-25

Management of  renal transplantation using Mizoribine

  • Online:2014-02-28 Published:2014-02-25

摘要:

摘要:肾移植术后免疫抑制剂的使用是肾移植后近期和远期存活率的重要影响因素。咪唑立宾作用机制与霉酚酸酯相似,既往咪唑立宾主要作为肾移植术后粒细胞减少、腹泻和预防感染的替代治疗药物,体现其独特优势,但是免疫抑制作用较弱可能会增加急性排斥反应发生率。而近期大剂量咪唑立宾应用在体现其优势的同时不会增加急性排斥反应发生率,有望作为一线用药。

关键词: 肾移植, 免疫抑制剂, 咪唑立宾, 感染

Abstract:

ABSTRACT Immunosuppressants play important roles on the short-term and long-term patient/graft survival in renal transplantation. Mizoribine (MZR) is similar to mycophenolate mofetil (MMF) in the mechanism of immunosuppression, and could be a substitute of MMF when the side-effects of MMF appear, like granulocytopenia, diarrhea or infection. The acute rejection rate may increase due to its less immunosuppressive in MZR group. However, high-dose MZR can reveal the advantage without increasing acute rejection rate, which can be selected as first-line treatment in the future.

Key words: renal transplantation,  immunosuppressant,  mizoribine,  infection